Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetic polymorphisms and GLP-1 RA efficacy in T2DM
NCT06256419Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Jan 2024
- Primary completion
- Jan 2028
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Change from baseline HbA1c at 6 months. Started Jan 2024; status: recruiting.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06256419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06256419.